Internal Medicine, Endocrinology, Diabetes, & Metabolism · Covington, KY
NPI
1114989886
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
1500 James Simpson Jr Way, Suite 200
Covington, KY, 41011
Phone (859) 655-8910
Groups this clinician bills Medicare through
Medicare paid, 2024
$34K
568 services
Medicare patients, 2024
173
Average age 71
Drug cost, 2024
$1.6M
4,930 prescriptions
Company payments, 2025
$2,588
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jaspreet K Chahal was code 99214 (office e&m - established), 296 times for 148 patients. In total Jaspreet K Chahal billed 568 services in 14 codes, and Medicare paid $34K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-09-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 296 | 148 | $85.70 | $25K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 112 | 83 | $11.60 | $1,299 |
| 95251 Test - Miscellaneous | Office | 66 | 37 | $23.44 | $1,547 |
| 99213 Office E&M - Established | Office | 37 | 33 | $54.16 | $2,004 |
| 99204 Office E&M - New | Office | 23 | 23 | $100.59 | $2,314 |
| 83036 Blood Count | Office | 14 | 13 | $9.52 | $133 |
By year: 2022 $35K for 491 services; 2023 $34K for 605 services; 2024 $34K for 568 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 14 | 13 | $9.52 | $133 |
Medicare prescription drug claims, 2024
In 2024, the drug Jaspreet K Chahal prescribed most often to Medicare patients was Levothyroxine Sodium, with 564 prescriptions and refills. In total Jaspreet K Chahal wrote 4,930 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 564 | 1,459 | 141 | $6,467 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 337 | 731 | 94 | $59K |
| Ozempic Semaglutide | 248 | 334 | 48 | $303K |
| Metformin Hcl Er Metformin Hcl | 236 | 672 | 80 | $1,794 |
| Atorvastatin Calcium Generic | 216 | 603 | 64 | $1,765 |
| Metformin Hcl Generic | 201 | 542 | 58 | $1,331 |
| Jardiance Empagliflozin | 194 | 350 | 44 | $200K |
| Lisinopril Generic | 173 | 472 | 50 | $880 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 164 | 325 | 56 | $17K |
| Rosuvastatin Calcium Generic | 162 | 431 | 46 | $1,189 |
| Novolog Flexpen Insulin Aspart | 114 | 234 | 45 | $32K |
| Glimepiride Generic | 97 | 280 | 34 | $487 |
| Droplet Pen Needle Pen Needle, Diabetic | 91 | 247 | 37 | $9,482 |
| Farxiga Dapagliflozin Propanediol | 90 | 181 | 21 | $93K |
| Testosterone Cypionate Generic | 87 | 97 | 13 | $2,217 |
Brand drugs: 2,246 claims; generic drugs: 2,214 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jaspreet K Chahal $2,588 ($2,588 in general payments such as food, travel and fees) from 31 companies. The largest payer was Novo Nordisk Inc with $418.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 25 | $418 |
| Abbott Laboratories ABT | 16 | $356 |
| Medtronic, Inc. MDT | 12 | $177 |
| Novartis Pharmaceuticals Corporation NVS | 9 | $156 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $140 |
| Lilly USA, LLC LLY | 8 | $118 |
| Sanofi-Aventis U.S. LLC SNY | 5 | $102 |
| CeQur Corporation | 1 | $86.11 |
| Neurocrine BioSciences, Inc. NBIX | 3 | $75.87 |
| Tandem Diabetes Care, Inc. TNDM | 2 | $74.83 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.